Moderna, bird flu

US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
U.S. pays $590 million to Moderna to speed up development of bird flu vaccine
The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top priority for the federal government.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna confirms $590M award by U.S. for bird flu vaccine development
Moderna (MRNA) announced ongoing support from the U.S. Department of Health and Human Services, HHS, to accelerate the development of
As bird flu concerns grow, scientists race to develop new vaccines
As fears grow of a possible bird flu pandemic in humans, the federal government is pouring more money into the development of new vaccines, including an mRNA shot.
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The package will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines, the ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
Is Moderna a Bad-News Buy for 2025?
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Jim Cramer Says Moderna, Inc. (MRNA) Is ‘So Luckless’
We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now?
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.